Ástralía - enska - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - ramipril -

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - ramipril, quantity: 5 mg - capsule, hard - excipient ingredients: meglumine; pregelatinised maize starch; titanium dioxide; brilliant blue fcf; sorbitan monolaurate; allura red ac; potable water; gelatin; sodium lauryl sulfate - treatment of hypertension. data are currently not available to support the use of ramipril ch capsules in renovascular hypertension. post mi heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or on antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - ramipril, quantity: 2.5 mg - capsule, hard - excipient ingredients: pregelatinised maize starch; meglumine; titanium dioxide; quinoline yellow; sorbitan monolaurate; allura red ac; potable water; gelatin; sodium lauryl sulfate - treatment of hypertension. data are currently not available to support the use of ramipril ch capsules in renovascular hypertension. post mi heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or on antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - ramipril, quantity: 1.25 mg - capsule, hard - excipient ingredients: meglumine; pregelatinised maize starch; titanium dioxide; iron oxide yellow; sorbitan monolaurate; potable water; gelatin; sodium lauryl sulfate - treatment of hypertension. data are currently not available to support the use of ramipril ch capsules in renovascular hypertension. post mi heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or on antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

bmdi tuta healthcare pty ltd -

Nígería - enska - NAFDAC (National Agency for Food and Drugs Administration and Control)

catheter, needle, vent plug

Nígería - enska - NAFDAC (National Agency for Food and Drugs Administration and Control)

plastic,needle, polyethylene bag: citric acid; 0.299g,sodium citrate;2.63g,monobasic sodium phospate;0.222g,dextrose:2.9g.water for injection to 100ml

Nígería - enska - NAFDAC (National Agency for Food and Drugs Administration and Control)

stainless steel,plastic

Nígería - enska - NAFDAC (National Agency for Food and Drugs Administration and Control)

stainless steel,plastic

Tansanía - enska - Tanzania Medicinces & Medical Devices Authority

generics & specialities limited, tanzania - catheters -